26 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
for the Company’s interactions with investors, employees, creditors, business partners, community members and other interested parties. The Company
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
, if approved, as safe and effective by patients and the healthcare community;
the maintenance of an acceptable safety profile of our product following any … products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
, employees, creditors, business partners, community members and other interested parties. The Company is committed to engaging with these stakeholders
424B3
NAMS
NewAmsterdam Pharma Company NV
12 Mar 24
Prospectus supplement
4:18pm
in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting
POS AM
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
60 days.
Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities
10-K
EX-10.9
8xdnhjz6ny3inv
28 Feb 24
Annual report
8:00am
10-K
zif50lndowe9 lq
28 Feb 24
Annual report
8:00am
10-K
EX-10.7
bidjisv72q97zlf8 5k
28 Feb 24
Annual report
8:00am
6-K
EX-99.1
dcx cqz17w
23 Oct 23
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
8:12am
424B3
hzqf520s
15 Aug 23
Prospectus supplement
4:52pm
POS AM
4ozy9llu iyiw
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
dwf9drqza358 zx
7 Aug 23
Research and development expenses
7:24am
424B3
5p14uf
8 Jun 23
Prospectus supplement
5:01pm
424B3
sy6obz7un68r8mb 0ba
6 Jun 23
Prospectus supplement
4:20pm
424B3
x5j557v 88
25 Apr 23
Prospectus supplement
8:14am
6-K
EX-99.1
7jb8led al06xy1ne7i
24 Apr 23
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating
8:08am
POS AM
grkzen12v
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
1m5wo 12tubkezdnds
19 Dec 22
Registration statement (foreign)
6:22pm
424B3
8k89c4mv 1i2somm
18 Oct 22
Prospectus supplement
4:41pm